The DNA damage response (DDR) has a critical role in maintaining genome integrity and serves as a barrier to tumorigenesis by promoting cell-cycle arrest, DNA repair, and apoptosis. The DDR is activated not only by genotoxic agents that induce DNA damage, but also during aberrant cell-division cycles caused by activated oncogenes and inactivated tumor suppressors. Here we use RNAi and cDNA overexpression screens in human cells to identify genes that, when deregulated, lead to activation of the DDR. The RNAi screen identified 73 genes that, when silenced in at least two cell types, cause DDR activation. Silencing several of these genes also caused an increased frequency of micronuclei, a marker of genetically unstable cells. The cDNA screen identified 97 genes that when overexpressed induce DDR activation in the absence of any exogenous genotoxic agent, with an overrepresentation of genes linked to cancer. Secondary RNAi screens identified CDK2-interacting protein (CINP) as a cell-cycle checkpoint protein. CINP interacts with ATR-interacting protein and regulates ATR-dependent signaling, resistance to replication stress, and G2 checkpoint integrity.
T
he DNA damage response (DDR) is regulated primarily by the activation of the ataxia telangiectasia-mutated (ATM) and ATM-and Rad3-related (ATR) kinases, which have unique and overlapping functions in promoting genome maintenance (1, 2) . While ATM responds primarily to DNA double-strand breaks (DSBs), ATR responds during every cell division cycle to replication stress and is essential for the viability of replicating somatic cells (3, 4) . The loss of ATR activity causes the formation of replicationassociated DSBs, presumably because of the inability of ATRdepleted cells to stabilize stalled forks (5) .
ATR signaling is regulated by several mechanisms, including protein-protein interactions, localization, and posttranslational modifications (2) . Recruitment of ATR to ssDNA generated at stalled forks is largely mediated by an interaction between its obligate binding partner, the ATR-interacting protein (ATRIP), and the heterotrimeric ssDNA binding protein replication protein A (RPA) (4, 6, 7) . An evolutionarily conserved RPA-binding surface in ATRIP, termed the ''checkpoint protein-recruitment domain,'' binds an N-terminal domain of RPA70 (8) .
ATR activation also requires topoisomerase binding protein 1 (TopBP1), which is a direct activator of ATR (9) . TopBP1 binds to the ATR-ATRIP complex primarily through a binding surface on ATRIP, with some contribution from a PIKK regulatory domain in ATR (10) . TopBP1 recruitment and positioning at the site of DNA damage is dependent on an interaction with the RAD9 subunit of a checkpoint clamp complex composed of RAD9-RAD1-HUS1 (9-1-1) (11) (12) (13) . TopBP1 also functions upstream of the 9-1-1 complex because 9-1-1 recruitment to sites of replication stress is dependent on TopBP1 (14) . Thus, multiple protein interactions promote the assembly of two checkpoint complexes (ATR-ATRIP and 9-1-1-TopBP1) at ssDNA gaps formed as a consequence of many types of DNA lesions.
Finally, there are additional modes of ATR-ATRIP regulation that remain poorly defined. ATRIP phosphorylation regulates the G2 checkpoint through an as yet undefined mechanism (15, 16) . Furthermore, ATRIP orthologues contain a coiled-coil region that has at least two functions. First, it allows ATRIP to form homodimers (17, 18) . ATRIP dimerization is required for stable association with ATR, and is therefore critical for proper ATR localization and signaling (17) . Second, an ATRIP mutant containing a heterologous coiled-coil dimerization domain restores the ability of ATRIP to form a stable complex with ATR, restores proper localization of the ATR-ATRIP complex to sites of replication stress and DNA damage, and can bind to TopBP1. However, it does not support efficient ATR-dependent checkpoint signaling when introduced into cells (17) . These data suggest there is an unidentified function for the ATRIP coiled-coil domain in regulating ATR signaling.
ATR and other DDR pathways are not only activated by endogenous and exogenous sources of DNA damage (such as radiation and reactive oxygen species), but also respond to tumorigenic gene-function defects that promote genome instability (19) . The overexpression or activation of oncogenes and inactivation of some tumor suppressors induces DDR activation in premalignant lesions, presumably because of aberrant cell-division cycles and replication stress (20) (21) (22) (23) (24) . These findings suggest a model whereby the ATM/ ATR-mediated DDR serves as a barrier to constrain tumor development by limiting cellular proliferation, inducing apoptosis, and promoting DNA repair (19) .
Several oncogenes and tumor suppressors that induce DDR activation when deregulated have been identified; however, the heterogeneity of cancer suggests there are many others that challenge genome integrity and promote tumorigenesis. We reasoned that we could identify cancer genes whose deregulation challenge genome integrity by monitoring DDR activation in cDNA overexpression and RNAi loss-of-function screens in otherwise untreated cells. Furthermore, we expected that the loss-of-function screen would identify previously unrecorded genome-maintenance genes, including those linked to the ATR-dependent replication checkpoint, as loss of ATR causes hyperactivation of the ATM signaling pathway. Indeed, we report the identification of over 170 genes that, when deregulated, cause an increase in DDR activity. These include an overrepresentation of cancer genes and a new regulator of the ATR checkpoint pathway: CDK2-interacting protein (CINP).
for genes that, when silenced or overexpressed, increase DDR signaling. Starting from a genome-wide shRNA library (25), we created a sublibrary of 6,386 RNAi molecules targeting 2,287 genes. Genes containing protein-domain architectures associated with nuclear regulatory activities were selected, thus increasing the possibility they may function in genome-maintenance pathways. HeLa cells were transfected with one shRNA vector per well in 96-well plates, and successfully transfected cells were identified by expression of GFP from the shRNA plasmids. DDR activation resulting from RNAi-mediated gene silencing was assayed in the absence and presence of a low dose of a replication stress agent (0.1 M aphidicolin) by immunofluorescence staining using a phosphopeptide-specific antibody to the ATM substrate KAP1 (KRAB domain-associated protein 1) (26) [Fig. 1A and Fig. S1 A] .
The primary RNAi screens identified 130 candidate genes whose silencing activated the DDR. To confirm this phenotype, eliminate off-target effects, and ensure the results were not cell-type or DDR-marker specific, we analyzed four individual siRNA oligonucleotides targeting each of the candidate genes. DDR activation was monitored in U2OS cells by examining phosphorylation of H2AX S139 (␥H2AX) (Fig. 1B and Fig. S1B ). ␥H2AX foci were observed in Ϸ1% of cells transfected with a nontargeting siRNA. In contrast, silencing of the ATR substrate checkpoint kinase 1 (CHK1) causes DDR activation in 59% of cells, consistent with previous observations (27) . The measurement of ␥H2AX foci as a high-throughput screening assay for DDR activation is robust, with the analyses of both untreated and low-dose aphidicolin-treated samples producing excellent Z-factor scores (0.61 and 0.59, respectively). The analysis of ␥H2AX identified 37 genes that met stringent statistical criteria, and an additional 36 genes that are strong candidates for possessing genome-maintenance activities (Table S1 and Table S2 ). This phenotype is unlikely to be off-target because at least three independent RNAi molecules targeting each gene activate the DDR (minimally, one shRNA and two siRNA molecules). Furthermore, DDR activation in two distinct cell types with two DDR markers indicates these gene products are not cell type-specific activities and do not regulate a specific ATM/ATR substrate.
Most genes identified in the RNAi screen increased DDR activation both in the absence and presence of aphidicolin. Of the 73 genes identified in the RNAi screen, silencing of 63 caused ␥H2AX phosphorylation in untreated U2OS cells and silencing of 72 genes caused ␥H2AX phosphorylation in the cells treated with low doses of aphidicolin; 62 genes were common to both datasets (Fig. S1C) .
As expected, gene products involved in nucleic acid metabolism and the cell cycle were prominent among those that exhibited genome-maintenance defects and DDR activation after RNAi silencing (Fig. 1C) . Additionally, 17 of the genes have been suggested to function as tumor suppressors (Table S3) , including 6 that were identified as breast and colorectal cancer genes by cancer genome-sequencing efforts (28, 29) . In addition to activating the DDR, three of these putative tumor-suppressor genes also caused micronuclei formation after RNAi silencing (CNTN4, S100A11, and OTOF) ( Table S4 ), a phenotype frequently used as a marker for chromosome breaks and genome instability.
cDNA Overexpression Screen. A three-step methodology was used to identify genes that, when overexpressed, cause activation of the DDR in the absence of any added genotoxic agents ( Fig. 2A) . First, pools of three cDNAs were cotransfected into HeLa cells with a GFP expression vector to identify successfully transfected cells. A total of 5,796 cDNAs expressed from the pCMV-SPORT6 vector were analyzed. Two days after transfection, cells were monitored for DDR activation by immunofluorescence staining for KAP1 phosphorylation. Second, the vectors from cDNA pools that caused KAP1 phosphorylation were deconvoluted and the KAP1 phosphorylation assay was repeated. Finally, individually positive cDNA vectors were transfected into a distinct cell type (U2OS) and DDR activation was monitored by immunofluorescence analysis of ␥H2AX.
A total of 97 genes were identified that caused DDR activation when overexpressed in both HeLa and U2OS cells ( Fig. 2B and Table S5 ). Gene products with biological functions linked to gene expression, cell-cycle regulation, nucleic acid metabolism, and cancer were strongly overrepresented when compared to the biological functions present within the cDNA screening library ( Fig. 2  C and D) . Among the genes linked to cancer (see Table S3 ) are several ets family transcription factors that act as oncogenes (30) . We confirmed that their overexpression activates the DDR even in untransformed epithelial cells ( Fig. 2 E and F) . Other oncogenes that induce DDR activation when overexpressed include DEK, ZBTB16 (PZLF), and ELAVL1 (HuR).
In some cases, both overexpression and silencing of a gene causes DDR activation. For example, we identified SMARCAL1 and members of the H2AFY histone family in both the siRNA and cDNA overexpression screens. SMARCAL1 encodes an annealing helicase that functions to maintain genome integrity at stalled replication forks (31) . We also found that overexpression of the mitotic kinase PLK1 activated the DDR, while silencing PLK1 was previously reported to cause DNA damage (32, 33) . To further understand the functional relationships between the genes identified in both the RNAi and cDNA overexpression screens, we performed an extensive bioinformatics analysis using published literature and functional annotation programs. This analysis placed many of the genes into four major functional groups: the ATM/ATR-related DDR, mitosis, chromatin regulation, and RNA metabolism (Fig. S2 ).
CINP Is a Checkpoint Gene. To characterize gene products from the RNAi screens that may be involved in ATR signaling, we developed a secondary assay for cellular sensitivity to hydroxyurea (HU) following RNAi silencing. The assay was optimized using silencing of ATR and validated by the results of the internal positive control CHK1, which cause a 70% and 50% reduction, respectively, in cell viability compared to the control ( Fig. 3A ; P Ͻ 0.001). Of the 73 genes identified in the RNAi screens, silencing 20 produced a significant HU-sensitivity score with at least two of four siRNAs (P Ͻ 0.05) (Table S6) .
One gene of particular interest is CINP. Silencing of CINP causes KAP1 phosphorylation in HeLa cells (three of five shRNAs), ␥H2AX foci formation in U2OS cells (three of four siRNAs), and sensitizes cells to HU treatment (three of four siRNAs) (Fig. 3 B-D , and see Table S1 , Table S2, and Table S6 ). Complementation of the HU-sensitivity and ␥H2AX phenotypes with an RNAi-resistant CINP cDNA indicates they are not off-target effects (Fig. 3 C and  E) . The ␥H2AX foci observed in CINP-silenced cells are likely to be sites of DNA damage because they colocalize with DNA repair proteins including Mre11 (Fig. 3F) .
CINP is distinctive among the genome maintenance genes because we also identified it as a candidate ATRIP-interacting protein. A yeast two-hybrid screen using full-length ATRIP as bait identified 11 cDNAs encoding interacting proteins, 2 of which were full-length CINP. The potential interaction of CINP with ATRIP, combined with the DNA damage and HU-sensitivity phenotypes resulting from loss of CINP, prompted us to characterize this potential ATR pathway protein further.
CINP Interacts with ATR-ATRIP Through the ATRIP Coiled-Coil Domain.
We first confirmed the association of CINP with ATR-ATRIP complexes by coimmunoprecipitation of exogenously expressed proteins. Immunoprecipitation of Flag-ATR or Flag-ATRIP from HEK293 cells coprecipitates HA-CINP (Fig. 4A) . The reciprocal immunoprecipitation indicates that Flag-CINP binds endogenous ATRIP. In contrast, we did not detect any interaction between CINP and ATM (Fig. 4B ). An interaction between endogenous ATR-ATRIP and CINP was also observed (Fig. 4C) . However, the interaction is likely to be transient or low affinity, as only a small percentage of these proteins were coimmunoprecipitated. The CINP-ATR-ATRIP interaction is not stimulated by DNA damage or replication stress (Fig. 4D) . Furthermore, subcellular localization studies on CINP showed pan-nuclear staining without any concentration into ATRIP-containing foci in response to DNA damage. These data suggest CINP may regulate ATR-ATRIP via transient interactions, and is not likely to be part of the active signaling complex at sites of DNA damage.
To further understand how CINP functions, we commissioned a two-hybrid screen to identify CINP-interacting proteins. To accomplish this, 75.5 million prey clones were screened using a full-length CINP bait. ATRIP was identified 12 times and was the only high-confidence CINP-interacting protein identified. All 12 ATRIP clones identified contained its coiled-coil domain. To further map the CINP binding surface on ATRIP, we used a two-hybrid prey library of thousands of random ATRIP fragments (7) in a targeted screen with full-length CINP as bait. Sequencing of the ATRIPinteracting fragments revealed that CINP binds to the N-terminal half of the predicted ATRIP coiled-coil domain containing the minimum amino acids 118 to 156 (Fig. 4E) . The interaction between CINP and the ATRIP coiled-coil domain was confirmed by coimmunoprecipitation. Flag-CINP coimmunoprecipitates HA-ATRIP and an ATRIP deletion mutant that retains amino acids 118 to 156; however, deletion of the ATRIP coiled-coil domain (⌬CC) eliminates the interaction with CINP (Fig. 4F) .
The ATRIP coiled-coil domain is required for ATRIP dimerization, stable ATR binding, accumulation of ATRIP at DNA lesions, and ATR-dependent checkpoint signaling (17, 18) . Replacement of this domain with the coiled-coil dimerization domain of the Saccharomyces cerevisiae GCN4 transcription factor restores all of these ATRIP functions except ATR-dependent CHK1 phosphorylation (17), suggesting there may be an activity of the coiledcoil domain in addition to promoting ATRIP oligomerization that is important to regulate ATR signaling. This activity may be binding of CINP, because replacement of the ATRIP coiled-coil domain with the GCN4 coiled-coil domain also fails to restore the interaction between ATRIP and CINP (see Fig. 4F ). Consistent with this interpretation, we found that cells expressing the ATRIP⌬CCϩGCN4 mutant in place of wild-type ATRIP are hypersensitive to HU (Fig. 4G) . Despite its functional defects in cells, the ATRIP⌬CCϩGCN4 protein does support TopBP1-dependent activation of ATR in vitro (Fig. S3A) . Similarly, CINP is not required for the TopBP1-activation of ATR in vitro (Fig. S3  C and D) .
To gain further evidence for a function of CINP in the ATR-ATRIP pathway, we examined whether CINP silencing impairs ATR-dependent signaling in response to genotoxic agents. Silencing of CINP significantly reduces CHK1 phosphorylation after both IR and UV radiation, although not to the extent that ATR silencing does (Figs. 5 A and B) . ATRdependent SMC1 phosphorylation is also impaired, indicating that CINP is required for efficient ATR signaling to multiple effector proteins. The CINP-dependency for ATR substrate phosphorylation is not the result of an indirect cell-cycle effect. CINP-depleted cells continue to proliferate. Cell-cycle analysis indicates there is a slight decrease in the percentage of G1-phase cells, an increase in G2-phase cells, and a similar percentage of S-phase cells in CINP-silenced cells compared to control (Fig.  5C ). These results are consistent with the mild checkpoint activation induced by CINP silencing in untreated cells.
Finally, we investigated whether CINP regulates the ATR- dependent checkpoint response. The G2 checkpoint is active and maintained in cells transfected with a nontargeting siRNA, as indicated by the low percentage of mitotic cells following irradiation ( Fig. 5 D and E) . In comparison, the percentage of cells escaping the G2 checkpoint following IR and UV treatment is increased in CINP-silenced populations, a phenotype also observed when ATRIP is silenced.
Discussion
Maintenance of genome integrity is critical for cancer prevention. We exploited markers of active DDR signaling to identify gene products important for maintaining genome integrity. We found that RNAi-mediated silencing of 73 genes, and the overexpression of 97 genes, increase DDR signaling.
Genome Maintenance and Cancer. As expected, many of the genes identified are suspected or known tumor suppressors or oncogenes (see Table S3 ). The cDNA overexpression screen found several oncogenes known to induce genetic instability when overexpressed, including PLK1, which causes chromosomal instability because of its function in centrosome and mitotic control (34) . Another interesting example is the DEK oncogene. DEK regulates chromatin and DNA topology, and was originally identified in a translocation in acute mylogenous leukemia (35) . DEK overexpression also suppresses the phenotypic defects of an ataxia-telangiectasia cell-line defective in ATM activity (36) . This suppression is cell-line specific and unique to a relatively mild ATM mutation (deletion of amino acids 2427 and 2428). Thus, DEK overexpression may cause chromatin changes that increase the activity of the mutant ATM protein, leading to partial suppression of the DNA damagesensitivity phenotype.
Our data indicate several ets family transcription factors cause DDR activation when overexpressed. Because these proteins are frequently overexpressed and amplified in human tumors (30) , they may contribute to tumorigenesis in part by promoting genome instability (19) . This is also true for other known or putative oncogenes identified in the overexpression screen. In some cases, gene overexpression may directly perturb genome maintenance activities, such as DNA repair. For example, HOXB7 is linked to DNA repair through interactions with PARP and DNA-PK proteins (37) , and its overexpression is associated with melanoma. Overexpression of the DNA repair proteins DCLRE1A and MLH1 may cause DNA damage via dominant negative effects because these proteins function as part of protein complexes.
Other major categories of genes identified in the screens include replication, mitotic control, and chromatin regulation. POLD1, POLA1, RBMS1, RFC5, RPA1, RPA2, RRM1, PRIM1, POLE2, and POLB are replication proteins whose silencing may cause increased replication stress. A group of genes that encode regulators of mitosis, including PLK1, WEE1, and APC subunits, may cause misregulated mitotic entry that could yield DNA damage either as a consequence of incomplete DNA replication or perhaps during the subsequent cell cycle. Several chromatin regulatory proteins, including multiple histones, HDAC7A, SETDB2, DEK, and ZNHIT4 were identified. In some cases the effect on genome maintenance may be indirect through transcriptional changes. In other cases, the chromatin regulation may directly affect DNA repair. For example, ZNHIT4 is an INO80 complex protein that is targeted to sites of DSBs. Chromatin regulation and DNA repair were also prominent categories of genes found in an S. cerevisiae screen that used increased spontaneous Rad52 foci as an assay (38) .
We also identified several proteins phosphorylated by ATM or ATR in response to DNA damage but with unknown functions, including PLEKHO2, SCFD1, MED13L, COPZ1, RBBP5, and PPP1R12C (39) . Our data confirm their placement in a DDR pathway.
Finally, in some cases it is unclear why deregulation of the genes we identified would lead to DDR activation. This is particularly the case in the cDNA overexpression screen. For example, a large number of RNA binding proteins not previously linked to DNA metabolism were found in the overexpression screen. In some of these cases, the effect may be indirect or could be because of induction of apoptosis. We excluded obvious apoptotic cells in our analysis, and the siRNA screen did not enrich for genes with known functions in apoptosis. We also have repeated the ␥H2AX screen using an apoptosis siARRAY library of RNAi molecules from Dharmacon and failed to identify any positive hits. However, in the cDNA overexpression screen we did identify CIDEC, CASP10, and CRADD that participate in apoptotic pathways. Thus, in some cases the ␥H2AX staining could be a result of the initiation of early stages of an apoptotic program.
CINP. CINP was originally identified in a two-hybrid screen for CDK2-interacting proteins (40) . However, nothing has been reported about its cellular function and we have not observed an interaction between CINP and CDK2 in either our two-hybrid or coimmunoprecipitation experiments. Our data identify CINP as a regulator of ATR-mediated checkpoint signaling. CINP forms a complex with ATR-ATRIP through ATRIP, promotes cell viability in response to replication stress, is required for efficient ATRdependent signaling after DNA damage, and is required for maintenance of the G2 checkpoint. CINP was also identified as a genome-maintenance protein in a recently published functional genomics screen (41) .
The need for CINP for full ATR signaling likely explains the defects associated with replacing the ATRIP-coiled-coil domain G2 checkpoint integrity after IR (D) or UV (E) radiation was examined in cells transfected with the indicated siRNAs. Mitotic cells were quantified by flow-cytometry analysis using a phospho-peptide specific antibody to histone H3 S10. Error bars represent standard error from three independent experiments. ATRIP and CINP siRNAs causing a statistically significant increase in the percentage of mitotic cells relative to the nontargeting control (NT) are designated by asterisks (two-tailed, unpaired t-test; * , P Ͻ 0.05, ** , P Ͻ 0.01).
with a heterologous coiled-coil domain (17) . The ATRIP-⌬CC-GCN4 protein is defective in promoting ATR-dependent CHK1 phosphorylation and G2 checkpoint control, yet it is capable of localizing the ATR complex to foci (17) and supporting TopBP1-dependent ATR activation in vitro (see Fig. S3 ). CINP binds the ATRIP coiled-coil domain and CINP-silencing mimics the functional defects of the ATRIP-⌬CC-GCN4 mutant. Therefore, CINP binding may be the second required activity of the ATIP coiled-coil domain, in addition to dimerization, that is important for ATR checkpoint signaling.
CINP is a small protein with no described domain structure beyond a predicted coiled-coil motif. Because CINP does not accumulate in DNA-damage foci with ATRIP, it may not be an integral component of the active ATR signaling complex. Furthermore, CINP is not needed to localize ATR-ATRIP to damageinduced foci or for the TopBP1-stimulated in vitro kinase activity of ATR-ATRIP complexes (see Fig. S3 ). We did observe a 50% reduction in ATRIP S224 phosphorylation in CINP-silenced cells (see Fig. S3 E and F) . S224 is phosphorylated by CDK2 (15) , suggesting that CINP regulates ATR signaling in part by controlling the cell-cycle-dependent phosphorylation of ATRIP. However, abolishing phosphorylation on this site completely using a S224A mutant does not fully mimic the phenotypes caused by CINP silencing, including the ␥H2AX induction and HU-hypersensitivity. Therefore, there are likely additional mechanisms by which CINP regulates ATR checkpoint function and genome maintenance.
Methods
RNAi, cDNA, and Yeast Two-Hybrid Screens. Details of these methodologies can be found in the SI Text. HU Sensitivity Screen. U2OS cells were transfected with siRNA and split into four 96-well plates the day after transfection. Three days after transfection, cells were incubated in media with (two plates) or without (two plates) 3 mM HU for 24 h, followed by 24 h in fresh growth media. Cell viability was quantified using the WST-1 cell-proliferation reagent (Roche). Sensitivity to HU was calculated by two methods. First, the ratio of the 450 nM absorbance for the mean of the two HU-treated wells to the mean of the two untreated wells was determined. Ratios for each gene-silencing siRNA were then normalized to the mean ratio of the nontargeting siRNAs within each plate to control for plate-to-plate variation. The log 2 of these viability ratios was calculated for determination of statistical significance. Second, the effect of siRNA silencing on HU sensitivity was calculated as an index of antagonism or sensitivity (see SI Text), taking into account the individual effects of the siRNA and the HU on cell viability (42) . The mean viability ratio and sensitivity-index values were calculated from three independent transfections, and statistical significance was determined using a two-tailed, unpaired t-test comparing each gene-silencing siRNA to the nontargeting siRNA.
